Abstract
The mechanisms by which patients infected with T. cruzi develop or not the disease are not completely understood. We investigated the importance of parasite persistence as a factor in generating cardiomyopathy. Fifty trypomastigote forms from the Tulahuen strain were used as inoculum for 160 Albino Swiss mice. Parasitemia, survival, histopathological and electrocardiographic studies were done on days 90, 180, 270 and 360 post infection (pi). Parasite presence in the tissues was determined by immunofluorescence. Maximum parasitemia was observed on day 21pi and became negative on day 42pi. By day 90pi, 50% of the infected mice presented electrocardiographic alterations and 67% by day 360pi; the non infected group of mice didn’t present elecrocardiographic alterations. Inflammatory infiltrates were observed throughout the infection, with a higher percentage in those mice with electrocardiographic alterations. The presence of the parasite was observed throughout the infection in skeletal muscle samples and on day 90pi in the myocardium. The highest mortality occurred on day 21pi, surviving 10% of the mice until the end of the experiments. These results demonstrate the presence of the parasite in the host tissues along the infection which could produce the injuries found in the myocardium and the electrocardiographic alterations.
Keywords: Trypanosoma cruzi, chagasic cardiomyopathy, persistence
Anti-Infective Agents
Title:Persistence of Trypanosoma cruzi in Experimental Chagasic Cardiomyopathy
Volume: 10 Issue: 2
Author(s): Bazan Carolina, Micucci Lorena, Fauro Romina, Triquel M. Fernanda, Lo Presti M. Silvina, Baez Alejandra, Strauss Mariana, Camino Gaston, Paglini-Oliva Patricia and Rivarola H. Walter
Affiliation:
Keywords: Trypanosoma cruzi, chagasic cardiomyopathy, persistence
Abstract: The mechanisms by which patients infected with T. cruzi develop or not the disease are not completely understood. We investigated the importance of parasite persistence as a factor in generating cardiomyopathy. Fifty trypomastigote forms from the Tulahuen strain were used as inoculum for 160 Albino Swiss mice. Parasitemia, survival, histopathological and electrocardiographic studies were done on days 90, 180, 270 and 360 post infection (pi). Parasite presence in the tissues was determined by immunofluorescence. Maximum parasitemia was observed on day 21pi and became negative on day 42pi. By day 90pi, 50% of the infected mice presented electrocardiographic alterations and 67% by day 360pi; the non infected group of mice didn’t present elecrocardiographic alterations. Inflammatory infiltrates were observed throughout the infection, with a higher percentage in those mice with electrocardiographic alterations. The presence of the parasite was observed throughout the infection in skeletal muscle samples and on day 90pi in the myocardium. The highest mortality occurred on day 21pi, surviving 10% of the mice until the end of the experiments. These results demonstrate the presence of the parasite in the host tissues along the infection which could produce the injuries found in the myocardium and the electrocardiographic alterations.
Export Options
About this article
Cite this article as:
Carolina Bazan, Lorena Micucci, Romina Fauro, M. Fernanda Triquel, Presti M. Silvina Lo, Alejandra Baez, Mariana Strauss, Gaston Camino, Patricia Paglini-Oliva and H. Walter Rivarola, Persistence of Trypanosoma cruzi in Experimental Chagasic Cardiomyopathy, Anti-Infective Agents 2012; 10 (2) . https://dx.doi.org/10.2174/2211362611208020136
DOI https://dx.doi.org/10.2174/2211362611208020136 |
Print ISSN 2211-3525 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-3533 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Interactive Effect of Combined Exposure to Active and Passive Smoking on Cardiovascular System
Recent Patents on Cardiovascular Drug Discovery Mass Spectrometry Data Analysis in the Proteomics Era
Current Bioinformatics Receptor Mediated Tumor Targeting: An Emerging Approach for Cancer Therapy
Current Drug Delivery Disease-Specific iPS Cell Models in Neuroscience
Current Molecular Medicine The GLUTs Family - Lessons from Transgenic Mice
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents EDITORIAL [Hot Topic: Transthyretin: A Small Protein in the Big World of Amyloidoses (Guest Editors: Adriano Martinelli and Gabriella Ortore)]
Current Medicinal Chemistry Determination of Stimulants and Diuretics in Dietary Supplements for Weight Loss and Physical Fitness by Ion-pair Chromatography and Pulsed Amperometric Detection (PAD)
Current Analytical Chemistry Chlorpyrifos with Age-Dependent Effects in Cardiac Tissue of Male Rats
Current Molecular Pharmacology Thymosin β4 Protein Therapy for Cardiac Repair
Current Pharmaceutical Design Editorial: [Hot Topic: Chromogranin A at the Crossroads of Health and Disease]
Current Medicinal Chemistry Sepsis-induced Cardiomyopathy
Current Cardiology Reviews Monitoring Cell Therapy Using Iron Oxide MR Contrast Agents
Current Pharmaceutical Biotechnology Estrogen Receptor-Positive and Estrogen Receptor-Negative Human Breast Cancer Cells: Regulation of Expression of Cancer-Related Genes by Estradiol and Tamoxifen
Current Signal Transduction Therapy Antioxidant Capacities of Flavones and Benefits in Oxidative-Stress Related Diseases
Current Topics in Medicinal Chemistry Effectors of Fatty Acid Oxidation Reduction: Promising New Anti-Ischaemic Agents
Current Pharmaceutical Design Biomarkers Associated with Bleeding Risk in the Setting of Atrial Fibrillation
Current Medicinal Chemistry Target-based Anti-angiogenic Therapy in Breast Cancer
Current Pharmaceutical Design Prevention of Ischemic Stroke: Antithrombotic Therapy in Cardiac Embolism
Current Drug Targets Phytochemicals as Prototypes for Pharmaceutical Leads Towards Drug Development Against Diabetic Cardiomyopathy
Current Pharmaceutical Design Meet the Editorial Board
Current Drug Targets